For research and educational purposes only. Not medical advice.
Dapagliflozin Reference
Educational, not medical advice reference for Dapagliflozin: Metabolic; regulatory status, evidence posture, source review, and schedule notes. Also known as…
Reference summary
DAPA-HF (McMurray 2019 NEJM, n=4,744 adults with heart failure and reduced EF) reported a 26 percent relative reduction in the primary composite of worsening heart failure or cardiovascular death - notably in patients with and without diabetes. DAPA-CKD established CKD benefit. DELIVER established benefit in heart failure with preserved EF. The cumulative dataset positioned dapagliflozin alongside empagliflozin as a foundational therapy for cardiometabolic disease.
Regulatory and posture
- Categories
- Metabolic
- Aliases
- Farxiga, Forxiga, SGLT2 inhibitor (small molecule, not a peptide)
- Evidence posture
- human
- Regulatory status
- FDA-approved as Farxiga (Forxiga in EU) for type 2 diabetes (2014), heart failure with reduced ejection fraction (2020), chronic kidney disease (2021), and heart failure across the ejection fraction spectrum (2023). Fixed-dose combinations with metformin (Xigduy XR) and saxagliptin (Qtern) are also approved.
- Content review status
- label verified